Skip to main content
Erschienen in: Endocrine 2/2021

15.10.2020 | Original Article

The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments

verfasst von: Victor Brun Boesen, Stina Willemoes Borresen, Thea Christoffersen, Marianne Klose, Torquil Watt, Ulla Feldt-Rasmussen

Erschienen in: Endocrine | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Replicating the physiological cortisol secretion is key in the treatment of glucocorticoid insufficient individuals and optimization may enhance quality of life. The study investigates fatigue measured by ecological momentary assessments in patients treated with conventional hydrocortisone compared with once-daily dual-release hydrocortisone (Plenadren).

Methods

A 21-week open-label switch pilot trial included 30 patients with adrenal insufficiency due to hypopituitarism. Fatigue was assessed four times daily for 20 days using a momentary item version of the Multidimensional Fatigue Inventory on patients’ usual hydrocortisone regimen. Participants switched treatment to an identical daily dose of Plenadren for 16 weeks where fatigue assessments were repeated. Change in fatigue and diurnal variation of fatigue was analyzed using mixed models for repeated measurements.

Results

In four out of five fatigue subscales fatigue was significantly reduced 0.7–1.1 points (scales ranging from 4 to 20), when treated with Plenadren compared with conventional hydrocortisone, corresponding to small effect sizes below the scale-specific minimal important changes. However, 33% of the participants completing the study (9/27) experienced reductions in fatigue above the minimal important change. On Plenadren, we found larger between-person variances and smaller within-person variances. Finally, we identified diurnal fatigue curves for both treatments.

Conclusions

The Plenadren-related reduction in fatigue was significant but not necessarily of clinical importance when looking at a group level. However, there was a large interindividual variation in treatment effect, why patients with a large benefit in quality of life should be identified. Future RCTs should be powered to detect the effect magnitudes identified here.
Literatur
1.
Zurück zum Zitat H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954 (2006).CrossRef H. Filipsson, J.P. Monson, M. Koltowska-Häggström, A. Mattsson, G. Johannsson, The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 91, 3954 (2006).CrossRef
2.
Zurück zum Zitat R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinol. Investig. 32, 917 (2009).CrossRef R. Giordano, S. Marzotti, M. Balbo, S. Romagnoli, E. Marinazzo, R. Berardelli, G. Migliaretti, A. Benso, A. Falorni, E. Ghigo, E. Arvat, Metabolic and cardiovascular profile in patients with Addison’s disease under conventional glucocorticoid replacement. J. Endocrinol. Investig. 32, 917 (2009).CrossRef
3.
Zurück zum Zitat L. Leelarathna, L. Breen, J.K. Powrie, S.M. Thomas, R. Guzder, B. McGowan, P.V. Carroll, Co-morbidities, management and clinical outcome of auto-immune Addison’s disease. Endocrine 38, 113 (2010).CrossRef L. Leelarathna, L. Breen, J.K. Powrie, S.M. Thomas, R. Guzder, B. McGowan, P.V. Carroll, Co-morbidities, management and clinical outcome of auto-immune Addison’s disease. Endocrine 38, 113 (2010).CrossRef
4.
Zurück zum Zitat J.W. Buning, M.Van. Faassen, P. Brummelman, R.P.F. Dullaart, G. Van Den Berg, M.M. Van Der Klauw, M.N. Kerstens, C.A. Stegeman, A.C.M. Kobold, I.P. Kema, B.H.R. Wolffenbuttel, A.P.Van. Beek, Effects of hydrocortisone on the regulation of blood pressure: results from a randomized controlled trial. J. Clin. Endocrinol. Metab. 101, 3691 (2016).CrossRef J.W. Buning, M.Van. Faassen, P. Brummelman, R.P.F. Dullaart, G. Van Den Berg, M.M. Van Der Klauw, M.N. Kerstens, C.A. Stegeman, A.C.M. Kobold, I.P. Kema, B.H.R. Wolffenbuttel, A.P.Van. Beek, Effects of hydrocortisone on the regulation of blood pressure: results from a randomized controlled trial. J. Clin. Endocrinol. Metab. 101, 3691 (2016).CrossRef
5.
Zurück zum Zitat E. Charmandari, N.C. Nicolaides, G.P. Chrousos, Adrenal insufficiency. Lancet 383, 2152 (2014).CrossRef E. Charmandari, N.C. Nicolaides, G.P. Chrousos, Adrenal insufficiency. Lancet 383, 2152 (2014).CrossRef
6.
Zurück zum Zitat A. Mallappa, M. Debono, Endocrine development: workshop, Rome, October 2014. Endocr. Dev. 30, 42 (2016).CrossRef A. Mallappa, M. Debono, Endocrine development: workshop, Rome, October 2014. Endocr. Dev. 30, 42 (2016).CrossRef
7.
Zurück zum Zitat S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364 (2016).CrossRef S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 364 (2016).CrossRef
8.
Zurück zum Zitat K. Løvås, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease*: Subjective health status in Addison’s disease. Clin. Endocrinol. (Oxf.) 56, 581 (2002).CrossRef K. Løvås, J.H. Loge, E.S. Husebye, Subjective health status in Norwegian patients with Addison’s disease*: Subjective health status in Addison’s disease. Clin. Endocrinol. (Oxf.) 56, 581 (2002).CrossRef
9.
Zurück zum Zitat S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.C. Koschker, M. Quinkler, O. Decker, W. Arlt, B. Allolio, Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912 (2007).CrossRef S. Hahner, M. Loeffler, M. Fassnacht, D. Weismann, A.C. Koschker, M. Quinkler, O. Decker, W. Arlt, B. Allolio, Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 92, 3912 (2007).CrossRef
10.
Zurück zum Zitat B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, B. Allolio, M. Quinkler, Impaired subjective health status in chronic adrenal insufficiency: Impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811 (2008).CrossRef B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, B. Allolio, M. Quinkler, Impaired subjective health status in chronic adrenal insufficiency: Impact of different glucocorticoid replacement regimens. Eur. J. Endocrinol. 159, 811 (2008).CrossRef
11.
Zurück zum Zitat B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, O. Decker, B. Allolio, M. Quinkler, Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin. Endocrinol. (Oxf.) 72, 297 (2010).CrossRef B. Bleicken, S. Hahner, M. Loeffler, M. Ventz, O. Decker, B. Allolio, M. Quinkler, Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin. Endocrinol. (Oxf.) 72, 297 (2010).CrossRef
12.
Zurück zum Zitat M. Forss, G. Batcheller, S. Skrtic, G. Johannsson, Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr. Disord. 12, 8 (2012).CrossRef M. Forss, G. Batcheller, S. Skrtic, G. Johannsson, Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr. Disord. 12, 8 (2012).CrossRef
13.
Zurück zum Zitat G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M.K. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473 (2012).CrossRef G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M.K. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473 (2012).CrossRef
14.
Zurück zum Zitat V. Guarnotta, A. Ciresi, G. Pillitteri, C. Giordano, Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin. Endocrinol. (Oxf.). 88, 665 (2018).CrossRef V. Guarnotta, A. Ciresi, G. Pillitteri, C. Giordano, Improved insulin sensitivity and secretion in prediabetic patients with adrenal insufficiency on dual-release hydrocortisone treatment: a 36-month retrospective analysis. Clin. Endocrinol. (Oxf.). 88, 665 (2018).CrossRef
15.
Zurück zum Zitat V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8, 853 (2019).CrossRef V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8, 853 (2019).CrossRef
16.
Zurück zum Zitat R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360 (2016).CrossRef R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360 (2016).CrossRef
17.
Zurück zum Zitat A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer, E. Sbardella, D. Gianfrilli, C. Pozza, P. Pasqualetti, S. Morrone, A. Santoni, F. Naro, A. Colao, R. Pivonello, A. Lenzi, Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173 (2018).CrossRef A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer, E. Sbardella, D. Gianfrilli, C. Pozza, P. Pasqualetti, S. Morrone, A. Santoni, F. Naro, A. Colao, R. Pivonello, A. Lenzi, Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 6, 173 (2018).CrossRef
18.
Zurück zum Zitat M. Quinkler, R.M. Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619 (2015).CrossRef M. Quinkler, R.M. Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619 (2015).CrossRef
19.
Zurück zum Zitat A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, O. Ragnarsson, S. Skrtic, J. Wahlberg, H. Achenbach, S. Uddin, C. Marelli, G. Johannsson, Long-Term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: A phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715 (2017).CrossRef A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, B.E. Engström, O. Ragnarsson, S. Skrtic, J. Wahlberg, H. Achenbach, S. Uddin, C. Marelli, G. Johannsson, Long-Term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: A phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715 (2017).CrossRef
20.
Zurück zum Zitat F. Ceccato, E. Selmin, C. Sabbadin, M. Dalla Costa, G. Antonelli, M. Plebani, M. Barbot, C. Betterle, M. Boscaro, C. Scaroni, Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965 (2018).CrossRef F. Ceccato, E. Selmin, C. Sabbadin, M. Dalla Costa, G. Antonelli, M. Plebani, M. Barbot, C. Betterle, M. Boscaro, C. Scaroni, Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965 (2018).CrossRef
21.
Zurück zum Zitat M. Øksnes, S. Bensing, A.L. Hulting, O. Kam̈pe, A. Hackemann, G. Meyer, K. Badenhoop, C. Betterle, A. Parolo, R. Giordano, A. Falorni, L. Papierska, W. Jeske, A.A. Kasperlik-Zaluska, V.K.K. Chatterjee, E.S. Husebye, K. Løvas, Quality of life in European patients with Addison’s disease:Validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568 (2012).CrossRef M. Øksnes, S. Bensing, A.L. Hulting, O. Kam̈pe, A. Hackemann, G. Meyer, K. Badenhoop, C. Betterle, A. Parolo, R. Giordano, A. Falorni, L. Papierska, W. Jeske, A.A. Kasperlik-Zaluska, V.K.K. Chatterjee, E.S. Husebye, K. Løvas, Quality of life in European patients with Addison’s disease:Validity of the disease-specific questionnaire AddiQoL. J. Clin. Endocrinol. Metab. 97, 568 (2012).CrossRef
22.
Zurück zum Zitat A. Stone, S. Shiffman, A. Atienza, L. Nebeling, The science of real-time data capture: self-reports in health research (Oxford University Press, Oxford; 2007). A. Stone, S. Shiffman, A. Atienza, L. Nebeling, The science of real-time data capture: self-reports in health research (Oxford University Press, Oxford; 2007).
23.
Zurück zum Zitat V.B. Boesen, U. Feldt-Rasmussen, J. Bue Bjorner, P. Cramon, M. Groenvold, B. Nygaard, Å.K. Rasmussen, T. Vilsbøll, T. Watt, How should thyroid-related quality of life be assessed? Recalled patient-reported outcomes compared to here-and-now measures. Thyroid 28, 1561 (2018).CrossRef V.B. Boesen, U. Feldt-Rasmussen, J. Bue Bjorner, P. Cramon, M. Groenvold, B. Nygaard, Å.K. Rasmussen, T. Vilsbøll, T. Watt, How should thyroid-related quality of life be assessed? Recalled patient-reported outcomes compared to here-and-now measures. Thyroid 28, 1561 (2018).CrossRef
24.
Zurück zum Zitat P. Lorenz, L. Schindler, S. Steudte-Schmiedgen, K. Weidner, C. Kirschbaum, J. Schellong, Ecological momentary assessment in posttraumatic stress disorder and coping. An eHealth study protocol. Eur. J. Psychotraumatol. 10, 1654064 (2019)CrossRef P. Lorenz, L. Schindler, S. Steudte-Schmiedgen, K. Weidner, C. Kirschbaum, J. Schellong, Ecological momentary assessment in posttraumatic stress disorder and coping. An eHealth study protocol. Eur. J. Psychotraumatol. 10, 1654064 (2019)CrossRef
25.
Zurück zum Zitat P. Solk, K. Gavin, J. Fanning, W. Welch, G. Lloyd, A. Cottrell, A. Nielsen, C.A.Santa. Maria, W. Gradishar, S.A. Khan, S. Kulkarni, J. Siddique, S.M. Phillips, Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer. Qual. Life Res 28, 3333 (2019).CrossRef P. Solk, K. Gavin, J. Fanning, W. Welch, G. Lloyd, A. Cottrell, A. Nielsen, C.A.Santa. Maria, W. Gradishar, S.A. Khan, S. Kulkarni, J. Siddique, S.M. Phillips, Feasibility and acceptability of intensive longitudinal data collection of activity and patient-reported outcomes during chemotherapy for breast cancer. Qual. Life Res 28, 3333 (2019).CrossRef
26.
Zurück zum Zitat M.J. Sliwinski, J.A. Mogle, J. Hyun, E. Munoz, J.M. Smyth, R.B. Lipton, Reliability and validity of ambulatory cognitive assessments. Assessment 25, 14 (2018).CrossRef M.J. Sliwinski, J.A. Mogle, J. Hyun, E. Munoz, J.M. Smyth, R.B. Lipton, Reliability and validity of ambulatory cognitive assessments. Assessment 25, 14 (2018).CrossRef
27.
Zurück zum Zitat S. Schneider, D.U. Junghaenel, F.J. Keefe, J.E. Schwartz, A.A. Stone, J.E. Broderick, Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: associations with psychological variables. Pain 153, 813 (2012).CrossRef S. Schneider, D.U. Junghaenel, F.J. Keefe, J.E. Schwartz, A.A. Stone, J.E. Broderick, Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: associations with psychological variables. Pain 153, 813 (2012).CrossRef
28.
Zurück zum Zitat V.B. Boesen, T. Christoffersen, T. Watt, S.W. Borresen, M. Klose, U. Feldt-Rasmussen, PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open. 8, 19487 (2018). V.B. Boesen, T. Christoffersen, T. Watt, S.W. Borresen, M. Klose, U. Feldt-Rasmussen, PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study. BMJ Open. 8, 19487 (2018).
29.
Zurück zum Zitat E.M.A. Smets, B. Garssen, B. Bonke, J.C.J.M. De Haes, The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39, 315 (1995).CrossRef E.M.A. Smets, B. Garssen, B. Bonke, J.C.J.M. De Haes, The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39, 315 (1995).CrossRef
30.
Zurück zum Zitat P. Cramon, Å.K. Rasmussen, S.J. Bonnema, J.B. Bjorner, U. Feldt-Rasmussen, M. Groenvold, L. Hegedüs, T. Watt, Development and implementation of PROgmatic: a clinical trial management system for pragmatic multi-centre trials, optimised for electronic data capture and patient-reported outcomes. Clin. Trials 11, 344 (2014).CrossRef P. Cramon, Å.K. Rasmussen, S.J. Bonnema, J.B. Bjorner, U. Feldt-Rasmussen, M. Groenvold, L. Hegedüs, T. Watt, Development and implementation of PROgmatic: a clinical trial management system for pragmatic multi-centre trials, optimised for electronic data capture and patient-reported outcomes. Clin. Trials 11, 344 (2014).CrossRef
31.
Zurück zum Zitat J.D. Fisk, P.G. Ritvo, L. Ross, D.A. Haase, T.J. Marrie, W.F. Schlech, Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 18, 79 (1994).CrossRef J.D. Fisk, P.G. Ritvo, L. Ross, D.A. Haase, T.J. Marrie, W.F. Schlech, Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 18, 79 (1994).CrossRef
32.
Zurück zum Zitat J.E. Ware, C.D. Sherbourne, The MOS 36-ltem short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care 30, 473 (1992).CrossRef J.E. Ware, C.D. Sherbourne, The MOS 36-ltem short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care 30, 473 (1992).CrossRef
33.
Zurück zum Zitat A. Purcell, J. Fleming, S. Bennett, B. Burmeister, T. Haines, Determining the minimal clinically important difference criteria for the multidimensional fatigue inventory in a radiotherapy population. Support. Care Cancer 18, 307 (2010).CrossRef A. Purcell, J. Fleming, S. Bennett, B. Burmeister, T. Haines, Determining the minimal clinically important difference criteria for the multidimensional fatigue inventory in a radiotherapy population. Support. Care Cancer 18, 307 (2010).CrossRef
34.
Zurück zum Zitat J. Cohen, Statistical power analysis for the behavioral sciences (Taylor & Francis Inc, New York, 2013). J. Cohen, Statistical power analysis for the behavioral sciences (Taylor & Francis Inc, New York, 2013).
35.
Zurück zum Zitat A.A. Stone, J.E. Schwartz, D. Schkade, N. Schwarz, A. Krueger, D. Kahneman, A population approach to the study of emotion: diurnal rhythms of a working day examined with the day reconstruction method. Emotion 6, 139 (2006).CrossRef A.A. Stone, J.E. Schwartz, D. Schkade, N. Schwarz, A. Krueger, D. Kahneman, A population approach to the study of emotion: diurnal rhythms of a working day examined with the day reconstruction method. Emotion 6, 139 (2006).CrossRef
Metadaten
Titel
The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments
verfasst von
Victor Brun Boesen
Stina Willemoes Borresen
Thea Christoffersen
Marianne Klose
Torquil Watt
Ulla Feldt-Rasmussen
Publikationsdatum
15.10.2020
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02507-x

Weitere Artikel der Ausgabe 2/2021

Endocrine 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.